CO6311109A2 - Nuevas secuencias de la brachyspira composiciones inmunogenicas metodos para la preparacion y su uso - Google Patents

Nuevas secuencias de la brachyspira composiciones inmunogenicas metodos para la preparacion y su uso

Info

Publication number
CO6311109A2
CO6311109A2 CO10118506A CO10118506A CO6311109A2 CO 6311109 A2 CO6311109 A2 CO 6311109A2 CO 10118506 A CO10118506 A CO 10118506A CO 10118506 A CO10118506 A CO 10118506A CO 6311109 A2 CO6311109 A2 CO 6311109A2
Authority
CO
Colombia
Prior art keywords
brachyspira
preparation
immunogenic compositions
new sequences
compositions methods
Prior art date
Application number
CO10118506A
Other languages
English (en)
Inventor
Matthew Bellgard
David John Hampson
Nyree D Phillips
Tom La
Original Assignee
Spirogene Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spirogene Pty Ltd filed Critical Spirogene Pty Ltd
Publication of CO6311109A2 publication Critical patent/CO6311109A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se describen el nuevo Polinucleótido y los aminoácidos de Brachyspira hyodysenteriae. Esas secuencias son de utilidad para el diagnostico de la enfermedad por Brachyspira hyodysenteriae en los animales y como un tratamiento terapéutico o tratamiento profiláctico de la enfermedad causada por la Brachyspira hyodysenteriae en los animales. Estas secuencias también pueden ser de utilidad para el diagnostico y tratamientos terapéuticos y /o profiláctico de enfermedades causadas en animales por otras especies de Brachyspira.
CO10118506A 2008-02-28 2010-09-24 Nuevas secuencias de la brachyspira composiciones inmunogenicas metodos para la preparacion y su uso CO6311109A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08152093A EP2363407A1 (en) 2008-02-28 2008-02-28 Novel sequences of Brachyspira, immunogenic compositions, methods for preparation and use thereof

Publications (1)

Publication Number Publication Date
CO6311109A2 true CO6311109A2 (es) 2011-08-22

Family

ID=39272375

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10118506A CO6311109A2 (es) 2008-02-28 2010-09-24 Nuevas secuencias de la brachyspira composiciones inmunogenicas metodos para la preparacion y su uso

Country Status (10)

Country Link
US (1) US20110064761A1 (es)
EP (1) EP2363407A1 (es)
JP (1) JP2011512803A (es)
KR (1) KR20100135762A (es)
AU (1) AU2009219116A1 (es)
BR (1) BRPI0908410A2 (es)
CA (1) CA2716973A1 (es)
CO (1) CO6311109A2 (es)
MX (1) MX2010009516A (es)
WO (1) WO2009105833A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101821284B (zh) * 2007-08-03 2014-11-19 贝林格尔·英格海姆维特梅迪卡有限公司 猪痢疾短螺旋体的基因和蛋白质及其用途
EP2593550A4 (en) * 2010-07-16 2014-01-22 Univ Saskatchewan DIAGNOSTIC METHOD OF COLITIS
WO2014096013A1 (en) 2012-12-21 2014-06-26 Boehringer Ingelheim Vetmedica Gmbh Novel recombinant outer membrane proteins from brachyspira hyodysenteriae and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622871A (en) 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
USRE31006E (en) 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
EP0043718B1 (en) 1980-07-07 1984-11-28 National Research Development Corporation Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4451570A (en) 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4632901A (en) 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
CA1319101C (en) 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
US4870007A (en) 1987-12-18 1989-09-26 Eastman Kodak Company Immobilized biotinylated receptor in test device, kit and method for determining a ligand
US5176910A (en) * 1989-01-17 1993-01-05 Ml Technology Ventures, L. P. Treponema hyodysenteriae hemolysin and uses therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
ZA918426B (en) 1990-10-31 1992-12-30 Akzo Nv Chicken anemia virus vaccine and diagnostic
EP0486106A3 (en) 1990-11-16 1992-12-23 Akzo N.V. Marek's disease virus vaccine
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5712118A (en) 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US6682729B1 (en) 1995-05-03 2004-01-27 University Of Maryland, Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US6150170A (en) 1998-05-03 2000-11-21 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
SE9602545L (sv) 1996-06-25 1997-12-26 Michael Mecklenburg Metod för att diskriminera komplexa biologiska prover
AU7164998A (en) 1997-04-28 1998-11-24 B-E Safe, Inc. Taxonomic identification of microorganisms, proteins and peptides involved in vertebrate disease states
EP1021548A1 (en) 1997-10-07 2000-07-26 University Of Maryland Biotechnology Institute Method for introducing and expressing rna in animal cells
US6500627B1 (en) 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
CA2390716A1 (en) 1999-09-24 2001-04-05 Alan D. King Process for enhancing electric field-mediated delivery of biological materials into cells
AU2001240109A1 (en) 2000-03-07 2001-09-17 U.S. Army Medical Research Institute Of Infectious Diseases Dna vaccines against poxviruses
AU2001250859A1 (en) 2000-03-16 2001-09-24 Joseph J. Drabick Method for gene transfection and vaccination through skin using electropermeabilization
BRPI0708959A2 (pt) * 2006-03-20 2011-06-28 Novartis Ag genes e proteìnas de brachyspira hyodysenteriae e uso dos mesmos para diagnóstico e terapia
CN101821284B (zh) * 2007-08-03 2014-11-19 贝林格尔·英格海姆维特梅迪卡有限公司 猪痢疾短螺旋体的基因和蛋白质及其用途

Also Published As

Publication number Publication date
AU2009219116A1 (en) 2009-09-03
MX2010009516A (es) 2010-11-30
JP2011512803A (ja) 2011-04-28
WO2009105833A1 (en) 2009-09-03
CA2716973A1 (en) 2009-09-03
EP2363407A1 (en) 2011-09-07
US20110064761A1 (en) 2011-03-17
KR20100135762A (ko) 2010-12-27
BRPI0908410A2 (pt) 2015-08-04

Similar Documents

Publication Publication Date Title
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
UY32427A (es) Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
CR9994A (es) Vacuna terapéutica
CO6331297A2 (es) Composiciones adyuvantes novedosas
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CR11042A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
AR058098A1 (es) Derivados de acidos dicarboxilicos y su uso
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
BR112014008700A2 (pt) composições úteis no tratamento de nefropatia e processos para preparação das mesmas
BRPI0923070A2 (pt) "usos de composições para regeneração e reparo de tecido neural após lesão, as referidas composições, e kit"
UY31676A1 (es) "derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
EA201170190A1 (ru) Фармацевтическая композиция, содержащая экстракт мозга свиньи
CL2014000050A1 (es) Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
AR053385A1 (es) Genes y proteinas novedosos de brachyspira hyodysenteriae y uso de los mismos para diagnostico y terapia
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
MX2010001381A (es) Genes y proteinas de brachyspira hyodysenteriae y usos de los mismos.
CO6311109A2 (es) Nuevas secuencias de la brachyspira composiciones inmunogenicas metodos para la preparacion y su uso
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria

Legal Events

Date Code Title Description
FA Application withdrawn